The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Associate Professor of Medicine (AIDS) and of Pharmacology, Yale
Principal investigator, PURPOSE 2
Articles by Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
5